- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 | 3 | Investing.com | ||
| 12.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | 76 | GlobeNewswire (Europe) | WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 08.04. | H.C. Wainwright reiterates Inhibikase stock rating on trial progress | 2 | Investing.com | ||
| 07.04. | Inhibikase: Erster Patient in Phase-3-Studie für Lungenhochdruck-Medikament aufgenommen | 3 | Investing.com Deutsch | ||
| 07.04. | Inhibikase startet Phase-3-Studie für Lungenhochdruck-Medikament mit erstem Patienten | 6 | Investing.com Deutsch | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.04. | Inhibikase enrolls first patient in Phase 3 PAH drug trial | 1 | Investing.com | ||
| 07.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 26.03. | Inhibikase Therapeutics GAAP EPS of -$0.49 | 1 | Seeking Alpha | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | 350 | GlobeNewswire (Europe) | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 21.01. | BofA Securities initiates coverage on Inhibikase stock with Buy rating | 6 | Investing.com | ||
| 29.12.25 | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | 3 | Investing.com | ||
| 29.12.25 | Jefferies bekräftigt Kaufempfehlung für Inhibikase-Aktie wegen beschleunigtem FDA-Verfahren | 8 | Investing.com Deutsch | ||
| 26.12.25 | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 26.12.25 | H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating | 3 | Investing.com | ||
| 19.12.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.11.25 | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | 265 | GlobeNewswire (Europe) | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 186,75 | +0,43 % | AbbVie's MAVIRET Secures Positive CHMP Opinion For Acute Hepatitis C Infection Treatment | WASHINGTON (dpa-AFX) - Friday, AbbVie Inc. (ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the... ► Artikel lesen | |
| TEVA | 29,400 | 0,00 % | Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749 | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries (TEVA), and Medincell announced that the European Medicines Agency has accepted the... ► Artikel lesen | |
| EYEPOINT | 11,100 | 0,00 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| ORGANIGRAM GLOBAL | 1,000 | +3,20 % | Organigram CEO sees Germany as launchpad for European expansion | ||
| QUANTUM BIOPHARMA | 7,815 | -2,19 % | Quantum Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| NEKTAR THERAPEUTICS | 58,00 | +1,08 % | Nektar Therapeutics Reports First Quarter 2026 Financial Results | SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.
Cash... ► Artikel lesen | |
| AMARIN | 12,500 | +1,63 % | Amarin Corporation plc: Amarin Reports 2026 First Quarter Financial Results | Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 208,70 | +1,02 % | Zanidatamab-Potenzial: Piper Sandler hebt Kursziel für Jazz Pharmaceuticals deutlich an | ||
| SELLAS LIFE SCIENCES | 6,760 | +0,90 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 440,50 | -1,19 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| XORTX THERAPEUTICS | 2,000 | +5,50 % | XORTX Therapeutics Inc (4): XORTX Therapeutics closes $5M (U.S.) public offering | ||
| BRIDGEBIO PHARMA | 58,96 | -1,01 % | BridgeBio Pharma, Inc.: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 | - Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified... ► Artikel lesen | |
| OPUS GENETICS | 3,700 | 0,00 % | Leerink startet Coverage für Opus Genetics mit "Outperform" und hohem Kursziel | ||
| RIGEL PHARMACEUTICALS | 23,990 | -4,12 % | RIGEL PHARMACEUTICALS INC - 8-K, Current Report | ||
| SAVARA | 4,278 | 0,00 % | Savara Inc. (SVRA) Reports Q1 Financial Results |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,695 Euro und damit +0,30 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.